Cannara Biotech Inc. (LOVE.TO) Stock Analysis

Company Overview

Cannara Biotech Inc. (LOVE.TO) is capitalised at CA$196.58M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. The company reports 452 employees.

Over the past 52 weeks the price has ranged from CA$1.55 to CA$2.07. The most recent close on file for LOVE.TO is CA$1.99, dated September 4, 2026. That is +CA$0.01 (+0.51%) against the previous close. The latest close sits 28.39% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is CA$117.33M. Profit margin runs at 9.25%. That is 12.4 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 0.11.

Valuation Assessment

The trailing P/E ratio stands at 18.09. That is 6.1% below the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 9.79. Measured against sales, the shares trade at 1.68 times revenue. On price-to-sales that is 27.04% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.37. Daily returns over the trailing 7 years annualize to a volatility of 380.72%. Over the trailing twelve months the price has returned +11.80%. Across 5 years the annualized return works out at +63.56%.

Growth & Income

The record shows no dividend for LOVE.TO.

The strongest complete calendar year on file is 2023 at +773.68%; the weakest is 2019 at −59.02%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the price is +14.37%.